v3.26.1
Cover - USD ($)
$ in Millions
 12 Months Ended
Mar. 31, 2026
Jun. 27, 2026
Sep. 30, 2025
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Mar. 31, 2026    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2026    
Current Fiscal Year End Date --03-31    
Entity File Number 001-15697    
Entity Registrant Name Elite Pharmaceuticals, Inc.    
Entity Central Index Key 0001053369    
Entity Tax Identification Number 22-3542636    
Entity Incorporation, State or Country Code NV    
Entity Address, Address Line One 165 Ludlow Avenue    
Entity Address, City or Town Northvale    
Entity Address, State or Province NJ    
Entity Address, Postal Zip Code 07647    
City Area Code (201)    
Local Phone Number 750-2646    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Trading Symbol ELTP    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 534
Entity Common Stock, Shares Outstanding   1,077,196,442  
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Auditor Name Forvis Mazars, LLP    
Auditor Location Iselin, NJ    
Auditor Firm ID 686    
Auditor Opinion [Text Block] We have audited the accompanying consolidated balance sheets of Elite Pharmaceuticals, Inc. (the “Company”) as of March 31, 2026 and 2025, the related consolidated statements of operations, shareholders’ equity, and cash flows for each of the years in the two-year period ended March 31, 2026, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of March 31, 2026 and 2025, and the results of its operations and its cash flows for each of the years in the two-year period ended March 31, 2026, in conformity with accounting principles generally accepted in the United States of America.